C Russell Trenary III Acquires 19,925 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) Stock

Outlook Therapeutics, Inc. (NASDAQ:OTLKGet Rating) CEO C Russell Trenary III acquired 19,925 shares of the business’s stock in a transaction that occurred on Tuesday, June 21st. The shares were bought at an average price of $1.06 per share, with a total value of $21,120.50. Following the completion of the transaction, the chief executive officer now directly owns 54,925 shares in the company, valued at $58,220.50. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Shares of OTLK traded up $0.01 during trading hours on Thursday, reaching $1.03. 253,607 shares of the company traded hands, compared to its average volume of 1,334,783. The stock has a market capitalization of $232.72 million, a PE ratio of -3.19 and a beta of 0.85. Outlook Therapeutics, Inc. has a fifty-two week low of $0.68 and a fifty-two week high of $3.27. The stock has a fifty day simple moving average of $1.41 and a 200 day simple moving average of $1.51.

Outlook Therapeutics (NASDAQ:OTLKGet Rating) last posted its quarterly earnings data on Friday, May 13th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). On average, equities analysts forecast that Outlook Therapeutics, Inc. will post -0.33 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its position in Outlook Therapeutics by 12.9% during the first quarter. BlackRock Inc. now owns 6,680,116 shares of the company’s stock worth $11,891,000 after buying an additional 761,356 shares during the period. State Street Corp lifted its position in Outlook Therapeutics by 6.3% during the first quarter. State Street Corp now owns 1,667,069 shares of the company’s stock worth $2,967,000 after buying an additional 99,312 shares during the period. Geode Capital Management LLC lifted its position in Outlook Therapeutics by 2.4% during the third quarter. Geode Capital Management LLC now owns 1,552,438 shares of the company’s stock worth $3,368,000 after buying an additional 36,351 shares during the period. Vista Finance LLC purchased a new position in Outlook Therapeutics during the first quarter worth about $1,751,000. Finally, Northern Trust Corp lifted its position in Outlook Therapeutics by 20.1% during the first quarter. Northern Trust Corp now owns 981,485 shares of the company’s stock worth $1,747,000 after buying an additional 163,940 shares during the period. Hedge funds and other institutional investors own 11.71% of the company’s stock.

About Outlook Therapeutics (Get Rating)

Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.

Read More

Insider Buying and Selling by Quarter for Outlook Therapeutics (NASDAQ:OTLK)

Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.